Drug Kinetics – Multimedia

This presentation was one of the keynote presentations from XenoTech's XenoTalks™ Seminar Series on the importance of ADME and Drug-Drug Interactions in drug development.

This informative ADME 101 discusses In Vitro to In Vivo Extrapolation (IVIVE) and how a model-based approach following routine perpetrator potential studies (i.e. CYP inhibition, CYP induction, and transporter inhibition) assessing clinical potential may eliminate the need of conducting clinical studies.

In early-stage pharmaceutical research, knowledge of a compound’s metabolism can assist in the identification of structural liabilities that can contribute to non-optimal pharmacokinetics, potentially toxic breakdown products or the potential for drug-drug interactions.

Speaking at Advances in Drug Discovery & Development online symposium 2021, Rolf Kern from SCIEX, presented his talk on the new Echo MS system.

This ADME 101 video discusses how compounds can become trapped by lysosomes, which can lead to high organ-to-blood ratios and mistaken for active drug transport, how concomitant administration of lysosomotropics could lead to elevated drug exposure levels, and how accumulation of lipophilic amines can lead to drug-induced phospholipidosis due to decreased phospholipid catabolism.

This ADME 101 video provides an overview of different types of subcellular fractions, such as microsomes, S9, cytosol, lysosomes and homogenate, and their unique benefits for use in various types of in vitro ADMET/DMPK & Drug-Drug Interaction studies.

In this Teach Me in 10 episode, Lucy Lawrence is joined by Dr. Andrew Mtewa, senior lecturer in chemistry at the Malawi University of Science and Technology.

Speaking at the online symposium, Innovations in Disease Modeling 2022, Dr. Donald E. Ingber, Founding Director of Wyss Institute for Biologically Inspired Engineering at Harvard University, presented his talk on novel human organ-on-a-chip technologies

Continuing our series on non-CYP-mediated metabolism pathways, we will be discussing another of the most requested enzymes: Sulfotransferases (SULTs). SULTs participate in Phase 2 metabolism of xenobiotics in humans and are characterized by the abundance and broad tissue distribution of the enzymes. Gene regulation and genetic polymorphism of SULTs also contribute to our understanding of the significance of these enzymes in the process of drug development.

Drug transport can be thought of as the AD&E in ADME, as transporters are responsible for absorption, distribution, tissue-specific drug targeting, and elimination of drugs. Since they are involved in so much of the movement of a compound through the body, they can be involved in many drug‒drug interactions (DDI). The clearance of transporter substrates can be impacted by transporter inhibitors or inducers which can lead to toxicity or loss of efficacy.